Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mucin polymer disulfide bridges are covalent bonds formed between cysteine residues of mucin polypeptides, enabling the polymerization of secreted mucins such as MUC2, MUC5AC, and MUC5B into large, gel-forming networks that constitute mucus on respiratory, gastrointestinal, and other mucosal surfaces[1][2][3][4][5][6]. These disulfide bridges are crucial for producing the viscoelastic and barrier properties of mucus. The process occurs during mucin biosynthesis in the secretory pathway, is regulated by pH and calcium, and is responsible for cross-linking mucin monomers into functional polymers. Dysfunctional formation or abnormal reduction of these bridges alters mucus structure and is implicated in various diseases characterized by impaired or excessive mucus, such as cystic fibrosis, COPD, and certain intestinal disorders[2][4][5][6].
Reducing agents (e.g., N-acetylcysteine) may cleave disulfide bonds in mucin polymers, reducing mucus viscosity indirectly. Inhibitors of mucin secretion may reduce overall polymer formation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mucin polymer disulfide bridge (null).